Dan S. Kaufman

Differentiation of embryonic stem cells towards hematopoietic cells: progress and pitfalls.

Differences in lymphocyte developmental potential between human embryonic stem cell and umbilical cord blood-derived hematopoietic progenitor cells.

Functional endothelial cells derived from rhesus monkey embryonic stem cells.

Mouse and human embryonic stem cell models of hematopoiesis: past, present, and future.

Efficient transfection of embryonic and adult stem cells.

Hematopoietic development of human embryonic stem cells in culture.

Hematopoietic development of human embryonic stem cells in culture.

Cytokine requirements differ for stroma and embryoid body-mediated hematopoiesis from human embryonic stem cells.

Synergistic use of adult and embryonic stem cells to study human hematopoiesis.

Nonhuman primate embryonic stem cells as a preclinical model for hematopoietic and vascular repair.

Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity.

Human embryonic stem cell-derived hematopoietic cells are capable of engrafting primary as well as secondary fetal sheep recipients.

Differentiation of human embryonic stem cells into hematopoietic cells by coculture with human fetal liver cells recapitulates the globin switch that occurs early in development.

Defined conditions for development of functional hepatic cells from human embryonic stem cells.

Hematopoietic engraftment of human embryonic stem cell-derived cells is regulated by recipient innate immunity.

Improved development of human embryonic stem cell-derived embryoid bodies by stirred vessel cultivation.

Derivation of normal macrophages from human embryonic stem (hES) cells for applications in HIV gene therapy.

Donor cell leukemia: insight into cancer stem cells and the stem cell niche.

Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer.

Wnt signaling promotes hematoendothelial cell development from human embryonic stem cells.

Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.

Hematopoietic development of human embryonic stem cells in culture.

Selective POTE paralogs on chromosome 2 are expressed in human embryonic stem cells.

Activation of hypoxic response in human embryonic stem cell-derived embryoid bodies.

Hematopoietic differentiation of human embryonic stem cells by cocultivation with stromal layers.

Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity.

Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.

Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells.

Bioluminescent imaging demonstrates that transplanted human embryonic stem cell-derived CD34(+) cells preferentially develop into endothelial cells.

Human embryonic stem cell-derived vascular progenitor cells capable of endothelial and smooth muscle cell function.

Use of human embryonic stem cells to understand hematopoiesis and hematopoietic stem cell niche.

Human embryonic stem cell-derived CD34+ cells function as MSC progenitor cells.

Pluripotent stem cell-derived natural killer cells for cancer therapy.

HIF hits Wnt in the stem cell niche.

Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms.

Methotrexate supports in vivo selection of human embryonic stem cell derived-hematopoietic cells expressing dihydrofolate reductase.

Induction of fracture repair by mesenchymal cells derived from human embryonic stem cells or bone marrow.

Extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation: better prognosis than systemic relapse.

A fibrin patch-based enhanced delivery of human embryonic stem cell-derived vascular cell transplantation in a porcine model of postinfarction left ventricular remodeling.

A synthetic substrate to support early mesodermal differentiation of human embryonic stem cells.

In vivo evaluation of putative hematopoietic stem cells derived from human pluripotent stem cells.

Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.

Concise review: Cord blood banking, transplantation and induced pluripotent stem cell: success and opportunities.

Erythroid-specific expression of β-globin from Sleeping Beauty-transduced human hematopoietic progenitor cells.

Bioenergetic and functional consequences of cellular therapy: activation of endogenous cardiovascular progenitor cells.

Pluripotent stem cells and gene therapy.

Functional consequences of human induced pluripotent stem cell therapy: myocardial ATP turnover rate in the in vivo swine heart with postinfarction remodeling.

RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells.

Engineered Human Embryonic Stem Cell-Derived Lymphocytes to Study In Vivo Trafficking and Immunotherapy.

Tu-mor(e) blood cells from human pluripotent stem cells.

Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy.

Mouse Xenograft Model for Intraperitoneal Administration of NK Cell Immunotherapy for Ovarian Cancer.

Fibrinogen Induces RUNX2 Activity and Osteogenic Development from Human Pluripotent Stem Cells.

Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells.

Single Cell Resolution of Human Hematoendothelial Cells Defines Transcriptional Signatures of Hemogenic Endothelium.

Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.

Advances in the role of the aryl hydrocarbon receptor to regulate early hematopoietic development.

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.

Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.

Development of innate immune cells from human pluripotent stem cells.

An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.

Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.

Human induced pluripotent stem cell-derived macrophages ameliorate liver fibrosis.

Into the multiverse of gene edited NK cell-based therapeutic strategies.

Disease-associated mutations in topoisomerase IIβ result in defective NK cells.

CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity.

Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy.

Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy.

CHMP2A regulates broad immune cell-mediated antitumor activity in an immunocompetent in vivo head and neck squamous cell carcinoma model.

Hemangiosarcoma Cells Promote Conserved Host-derived Hematopoietic Expansion.

Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells.

Next-generation macrophages: repolarizing CAR-macrophages against cancer.